JhanelleEGrayMD

Physician

Overview of Dr. Gray

Dr. Jhanelle Gray is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. She received her medical degree from Weill Cornell Medicine and has been in practice 16 years. Dr. Gray accepts several types of health insurance, listed below. She is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
12902 Usf Magnolia Dr
# Fob
Tampa, FL 33612
Book by Phone+1(440) 682-1015

Fax+1 813-745-3027

Education & Training

University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2004 - 2007
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2004
Weill Cornell MedicineClass of 2001

Certifications & Licensure

FL State Medical License 2004 - 2025
NY State Medical License 2003 - 2005
American Board of Internal Medicine Medical Oncology

Clinical Trials

Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers Start of enrollment: 2008 Nov 01
Completed
Phase 1
Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer Start of enrollment: 2012 Mar 26
Completed
Phase 1, Phase 2
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer Start of enrollment: 2013 Sep 09
Terminated
Phase 1
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation Start of enrollment: 2013 Dec 30
Completed
Phase 1
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2013 Dec 31
Completed
Phase 1
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases Start of enrollment: 2014 Oct 09
Terminated
Phase 1
Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2016 Mar 22
Active, not recruiting
Phase 1, Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC Start of enrollment: 2017 Dec 20
Completed
Phase 1, Phase 2
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer Start of enrollment: 2018 Feb 02
Active, not recruiting
Phase 1, Phase 2
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer Start of enrollment: 2019 Nov 05
Active, not recruiting
Phase 3
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC Start of enrollment: 2020 Nov 23
Terminated
Phase 1
AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer Start of enrollment: 2015 Oct 30
Completed
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

98 citations
Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases.
Kamran Ahmed, Sungjune Kim, John A. Arrington, Arash O. Naghavi, Thomas J. Dilling
Journal of Neuro-Oncology. 2017-05-02
188 citations
Structure-based classification predicts drug response in EGFR-mutant NSCLC
Jacqulyne P. Robichaux, Xiuning Le, R. S. K. Vijayan, J. Kevin Hicks, Simon Heeke
Nature. 2021-09-15
3030 citations
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong
The New England Journal of Medicine. 2018-01-11

Journal Articles

Overall Survival with Durvalumab After Chemoradiotherapy in Stage III NSCLC
David R Spigel, Davey Daniel, Jhanelle E Gray, Augusto Villegas, Tarek Mekhail, Alberto Chiappori, The New England Journal of Medicine

Lectures

Lung Cancer—Non-Small Cell Metastatic
ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019
Three-year overall survival update from the PACIFIC trial.
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer CenterSeptember 24th, 2024
‘Astonishing’ 4-Year Survival in NSCLC with Pembro plus ChemoFebruary 4th, 2021
John Cleveland: How Moffitt Will Heal from Conflict of Interest Trauma—and from COVID-19May 29th, 2020
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna HMO
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment